RSS | Login | Register

DIOVAN

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare DIOVAN to:

Generic Name for DIOVAN

Valsartan 40mg+, 80mg, 160mg, 320mg; +scored; tabs.

Legal Classification:

Pharmacological Class for DIOVAN

Angiotensin II receptor blocker.

Manufacturer of DIOVAN

Novartis Pharmaceuticals Corp

Indications for DIOVAN

Heart failure (NYHA Class II–IV). To reduce cardiovascular mortality in stable post-MI patients with left ventricular failure or dysfunction.

Adult dose for DIOVAN

Heart failure: initially 40mg twice daily, increase to 80mg twice daily, then to 160mg twice daily as tolerated. Post-MI: may start 12hrs post-MI; initially 20mg twice daily, increase within 1 wk to 40mg twice daily; target maintenance: 160mg twice daily as tolerated. Low BP or renal dysfunction: reduce dose.

Children's dosing for DIOVAN

Not recommended.

Contraindications for DIOVAN

Pregnancy (Cat.D in 2^ndand 3^rdtrimesters).

Warnings/Precautions for DIOVAN

Correct hypovolemia before beginning therapy (may need to reduce diuretic) or monitor closely for hypotension. Hepatic or severe renal impairment. Renal artery stenosis. Severe CHF (if renal function depends on renin-angiotensin-aldosterone system). Pregnancy (Cat.C in 1^sttrimester). Nursing mothers: not recommended.

Interactions for DIOVAN

Concomitant K⁺ supplements, K⁺sparing diuretics, K⁺containing salt substitutes may lead to hyperkalemia and, in heart failure patients, increased serum creatinine. Concomitant ACE inhibitor and β-blocker (see literature regarding heart failure patients).

Adverse Reactions for DIOVAN

Dizziness, hypotension, diarrhea, hyperkalemia, increased BUN, neutropenia, rhabdomyolysis (rare).

How is DIOVAN supplied?

Tabs 40mg—30
Tabs 80mg, 160mg, 320mg—90

Related Disease:

CHF and arrhythmias {CHF and arrhythmias}

Lundbeck recalls two lots of NeoProfen

August 02, 2010

Lundbeck announced a voluntary nationwide recall of two lots of NeoProfen (ibuprofen lysine) Injection that failed to meet a visible particulate quality requirement.

Generic Lovenox approved for anticoagulation

July 26, 2010

The FDA has granted Sandoz approval of a generic version of Lovenox (enoxaparin sodium injection, from sanofi aventis).

FDA warns of dangerous ingredients in Joyful Slim herb supplement

July 22, 2010

The FDA is warning consumers that Joyful Slim herb supplement, marketed as a natural herb for weight loss, contains undeclared desmethyl sibutramine, an FDA-approved drug used as an appetite suppressant for weight loss.

FDA conducts safety review of cancer risk with angiotensin receptor blockers (ARBs)

July 15, 2010

A recently published meta-analysis combining cancer-related findings from several clinical trials is suggesting that angiotensin receptor blockers (ARBs) may be associated with a small increased risk of cancer.

Phase 3 study of Brinavess for the treatment of atrial fibrillation (AF)

May 17, 2010

Merck and Cardiome Pharma announced results from their Phase 3 trial of Brinavess (vernakalant intravenous injection) for the treatment of atrial fibrillation (AF).